Clinical Trial to Evaluate the Safety and Efficacy of IM92 CAR-T Cells Therapy in Patients With Advanced Gastric or Pancreatic Adenocarcinoma

NCT05275062 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

UNKNOWN

Status

6

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors
Gastric Cancer
Esophagogastric Junction Cancer
Pancreatic Cancer

Interventions

DRUG: IM92 CAR-T cells

Sponsor

Beijing Immunochina Medical Science & Technology Co., Ltd.